The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. SMA Europe awards 4 new grants to cutting-edge research projects

    SMA research receives vital funds from SMA Europe. Based on the recommendations received by its Scientific Advisory Board, SMA Europe awarded a total of 544,900 Euros to 4 cutting-edge SMA research projects through its 10th Call for Research Proposals. The Scientific Advisory Board reviewed and scored 19 very high level SMA research proposals. As only […]


  2. FDA puts partial hold on AVXS-101 intrathecal clinical trials for SMA

    Novartis announced this morning that the Food and Drug Administration (FDA) in the US has placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal study. Zolgensma® , also known as AVXS-101 intravenous administration is not impacted and remains available in the US. Novartis is […]


  3. Biogen announces new nusinersen trial in broad patient population

    Biogen has announced that it will conduct a new global clinical trial,  DEVOTE. The study will evaluate if higher dosing of nusinersen can provide  improved efficacy in the treatment of SMA across a broad population of patients. The study aims to further build on the long-term safety profile and efficacy of nusinersen in a projected […]


  4. A community update from Biogen

    Following a request from SMA Europe, Biogen has released the following community updates on: Access to Spinraza™ : 28 European countries now have access to Spinraza™ for 5q SMA Types I, II and III, via regular reimbursement but in some cases, including age restrictions. Additionally, in certain countries there are rare disease/ medical committees who […]